pyrimethamine has been researched along with AIDS-Related Opportunistic Infections in 113 studies
Maloprim: contains above 2 cpds
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 9.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "In this international, noncomparative, randomized phase II trial, we evaluated the effectiveness and tolerance of atovaquone suspension (1500 mg orally twice daily) plus either pyrimethamine (75 mg per day after a 200-mg loading dose) or sulfadiazine (1500 mg 4 times daily) as treatment for acute disease (for 6 weeks) and as maintenance therapy (for 42 weeks) for toxoplasmic encephalitis (TE) in patients infected with human immunodeficiency virus." | 9.10 | Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche ( Andersen, J; Bosler, EM; Chirgwin, K; Hafner, R; Jayaweera, DT; Leport, C; Luft, BJ; McAuliffe, V; Morlat, P; Rajicic, N; Remington, J; Roque, C; Vilde, JL, 2002) |
| "An open, randomised, multicentre trial was conducted to evaluate the efficacy of thrice-weekly versus daily therapy with sulfadiazine-pyrimethamine in the prevention of relapses of toxoplasmic encephalitis in HIV-infected patients." | 9.09 | Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. ( Arrizabalaga, J; Cosin, J; Cruceta, A; Domingo, P; Fariñas, MC; Ferrer, E; Gatell, JM; Gudiol, F; Knobel, H; Leyes, M; Martínez-Lacasa, J; Miró, JM; Podzamczer, D; Polo, R; Ramón, JM; Ribera, E; Sirera, G, 2000) |
| "To assess the safety, tolerance and activity of increasing doses of azithromycin in combination with pyrimethamine for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 9.09 | Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. ( Bosler, EM; Farthing, C; Hafner, R; Harris, C; Holden-Wiltse, J; Jacobson, JM; Jayaweera, DT; Luft, BJ; Remington, J; Roque, C, 2001) |
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 9.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly was assessed as primary prophylaxis for toxoplasmic encephalitis (TE) in 554 human immunodeficiency virus-infected patients seropositive for Toxoplasma gondii and with < 200 CD4 cells/mm3." | 9.08 | Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Gr ( Aubertin, J; Chêne, G; Hafner, R; Leport, C; Luft, BJ; Miro, J; Morlat, P; Pueyo, S; Rousseau, F; Salamon, R; Vildé, JL, 1996) |
| "The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS." | 9.08 | Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. ( Angarano, G; Carosi, G; Casari, S; Chiodo, F; Donisi, A; Fiori, G; Gregis, G; Orani, A; Poggio, A; Ranieri, S; Speranza, F; Torre, D, 1998) |
| "Between February 1990 and June 1993, 105 patients with HIV infection were enrolled after each had had resolution of an acute episode of toxoplasmic encephalitis treated with sulfadiazine (1 g four times per day) plus pyrimethamine (50 mg/d) plus folinic acid (15 mg/d) for 4 to 8 weeks." | 9.08 | Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. ( Bolao, F; Cosín, J; Domingo, P; Gatell, JM; Laguna, F; Miró, JM; Podzamczer, D; Santamaría, J; Sirera, G; Verdejo, J, 1995) |
| "This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (Pyr-Sdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 9.08 | Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. ( Clumeck, N; De Wit, S; Katlama, C; O'Doherty, E; Van Glabeke, M, 1996) |
| "A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acute Toxoplasma encephalitis in patients with AIDS." | 9.07 | Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. ( Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993) |
| "To monitor the effectiveness of intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) for the control of malaria in pregnancy at delivery in the Provincial Hospital in Kisumu, Kenya, and to assess the effect of IPT in participants in a cohort study." | 7.72 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "To evaluate the safety and efficacy of a fixed 25mg pyrimethamine--500mg sulfadoxine combination plus 15mg folinic acid given twice weekly for the prevention of relapses of Pneumocystis carinii pneumonia (PCP) and primary episodes of toxoplasmic encephalitis." | 7.71 | Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS. ( Albrecht, H; Behnsch, M; Bergmann, F; Grobusch, M; Grünewald, T; Padberg, J; Ruf, B; Schürmann, D; Suttorp, N; Vallée, M; Wünsche, T, 2001) |
| "The efficacy and safety of 25 mg pyrimethamine plus 500 mg sulfadoxine given twice a week in preventing relapses of AIDS-related toxoplasmic encephalitis was evaluated in an open study." | 7.68 | Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. ( Bergmann, F; Gottschalk, HJ; Grünewald, T; Pohle, HD; Ruf, B; Schüler-Maué, W; Schürmann, D; Witt, H, 1993) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 5.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "In this international, noncomparative, randomized phase II trial, we evaluated the effectiveness and tolerance of atovaquone suspension (1500 mg orally twice daily) plus either pyrimethamine (75 mg per day after a 200-mg loading dose) or sulfadiazine (1500 mg 4 times daily) as treatment for acute disease (for 6 weeks) and as maintenance therapy (for 42 weeks) for toxoplasmic encephalitis (TE) in patients infected with human immunodeficiency virus." | 5.10 | Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche ( Andersen, J; Bosler, EM; Chirgwin, K; Hafner, R; Jayaweera, DT; Leport, C; Luft, BJ; McAuliffe, V; Morlat, P; Rajicic, N; Remington, J; Roque, C; Vilde, JL, 2002) |
| "An open, randomised, multicentre trial was conducted to evaluate the efficacy of thrice-weekly versus daily therapy with sulfadiazine-pyrimethamine in the prevention of relapses of toxoplasmic encephalitis in HIV-infected patients." | 5.09 | Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. ( Arrizabalaga, J; Cosin, J; Cruceta, A; Domingo, P; Fariñas, MC; Ferrer, E; Gatell, JM; Gudiol, F; Knobel, H; Leyes, M; Martínez-Lacasa, J; Miró, JM; Podzamczer, D; Polo, R; Ramón, JM; Ribera, E; Sirera, G, 2000) |
| "To assess the safety, tolerance and activity of increasing doses of azithromycin in combination with pyrimethamine for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 5.09 | Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. ( Bosler, EM; Farthing, C; Hafner, R; Harris, C; Holden-Wiltse, J; Jacobson, JM; Jayaweera, DT; Luft, BJ; Remington, J; Roque, C, 2001) |
| "Between February 1990 and June 1993, 105 patients with HIV infection were enrolled after each had had resolution of an acute episode of toxoplasmic encephalitis treated with sulfadiazine (1 g four times per day) plus pyrimethamine (50 mg/d) plus folinic acid (15 mg/d) for 4 to 8 weeks." | 5.08 | Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. ( Bolao, F; Cosín, J; Domingo, P; Gatell, JM; Laguna, F; Miró, JM; Podzamczer, D; Santamaría, J; Sirera, G; Verdejo, J, 1995) |
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 5.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (Pyr-Sdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 5.08 | Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. ( Clumeck, N; De Wit, S; Katlama, C; O'Doherty, E; Van Glabeke, M, 1996) |
| "Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly was assessed as primary prophylaxis for toxoplasmic encephalitis (TE) in 554 human immunodeficiency virus-infected patients seropositive for Toxoplasma gondii and with < 200 CD4 cells/mm3." | 5.08 | Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Gr ( Aubertin, J; Chêne, G; Hafner, R; Leport, C; Luft, BJ; Miro, J; Morlat, P; Pueyo, S; Rousseau, F; Salamon, R; Vildé, JL, 1996) |
| "The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS." | 5.08 | Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. ( Angarano, G; Carosi, G; Casari, S; Chiodo, F; Donisi, A; Fiori, G; Gregis, G; Orani, A; Poggio, A; Ranieri, S; Speranza, F; Torre, D, 1998) |
| "Oral clindamycin and pyrimethamine are an effective treatment for toxoplasmic encephalitis." | 5.07 | Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. ( Antoniskis, D; Bosler, EM; Bourland, DD; Fuhrer, J; Hafner, R; Jacobson, J; Korzun, AH; Leport, C; Luft, BJ; Uttamchandani, R, 1993) |
| "A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acute Toxoplasma encephalitis in patients with AIDS." | 5.07 | Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. ( Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993) |
| "The intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) has been a key component of the focused antenatal care package for nearly a decade, reducing the burden of low birthweight attributable to malaria in sub-Saharan Africa." | 4.87 | Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. ( Chandramohan, D; Chico, RM, 2011) |
| "In a meta-analysis, we examined the efficacy of aerosolized pentamidine, trimethoprim-sulfamethoxazole, and dapsone or dapsone/pyrimethamine for the prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in patients with HIV infection." | 4.79 | Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. ( Bucher, HC; Griffith, L; Guyatt, GH; Opravil, M, 1997) |
| "To monitor the effectiveness of intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) for the control of malaria in pregnancy at delivery in the Provincial Hospital in Kisumu, Kenya, and to assess the effect of IPT in participants in a cohort study." | 3.72 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "To evaluate the safety and efficacy of a fixed 25mg pyrimethamine--500mg sulfadoxine combination plus 15mg folinic acid given twice weekly for the prevention of relapses of Pneumocystis carinii pneumonia (PCP) and primary episodes of toxoplasmic encephalitis." | 3.71 | Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS. ( Albrecht, H; Behnsch, M; Bergmann, F; Grobusch, M; Grünewald, T; Padberg, J; Ruf, B; Schürmann, D; Suttorp, N; Vallée, M; Wünsche, T, 2001) |
| " Malaria prevalence at delivery remained high in HIV-infected women despite prior routine treatment with sulphadoxine-pyrimethamine in pregnancy There was no significant difference in parasite prevalence at delivery between women who did or did not use sulphadoxine-pyrimethamine." | 3.70 | Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Hart, CA; Kazembe, P; Verhoeff, FH, 1999) |
| " We illustrate all of our comparisons with a dataset from an AIDS clinical trial that compared the effectiveness of the drug pyrimethamine and a placebo in preventing toxoplasmic encephalitis." | 3.69 | Robust Bayesian approaches for clinical trial monitoring. ( Carlin, BP; Sargent, DJ, 1996) |
| "The efficacy and safety of 25 mg pyrimethamine plus 500 mg sulfadoxine given twice a week in preventing relapses of AIDS-related toxoplasmic encephalitis was evaluated in an open study." | 3.68 | Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. ( Bergmann, F; Gottschalk, HJ; Grünewald, T; Pohle, HD; Ruf, B; Schüler-Maué, W; Schürmann, D; Witt, H, 1993) |
| " However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial." | 2.73 | Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mubikayi, L; Mukwamataba, D; Mulele, CK; Mulenga, M; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "Pyrimethamine was administered at 50 mg daily for 3 weeks to achieve steady state, and pharmacokinetic profiles were determined after administration of the last dose." | 2.68 | Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ( Davidian, M; Hafner, R; Jacobson, JM; Luft, BJ; Raasch, RH; Rainey, PM, 1996) |
| " The weekly dosage of pyrimethamine ranged from 25 to 1,400 mg; one patient with severe diarrhea received 2,100 mg/week." | 2.68 | Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. ( Klinker, H; Langmann, P; Richter, E, 1996) |
| "Cerebral toxoplasmosis is the most frequent opportunistic infection in patients with acquired immune deficiency syndrome in France." | 2.67 | [Primary prophylaxis against cerebral toxoplasmosis. Efficacy of folinic acid in the prevention of hematologic toxicity of pyrimethamine]. ( Barbeau, P; Brossard, G; Leng, B; Neau, D; Pellegrin, JL, 1994) |
| " The pharmacokinetics of dapsone and pyrimethamine were examined by using a population pharmacokinetic model." | 2.67 | Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. ( Amantea, MA; Byrne, A; Davey, RT; Falloon, J; Graziani, A; Lavelle, J; Morgan, A; Ogata-Arakaki, D; Ownby, K; Polis, M, 1994) |
| " gondii pneumonia should use the synergistic combination of pyrimethamine and a sulfa-based antibiotic, optimal prophylactic antibiotic combinations and dosing schedules for recurrent infection are still being investigated." | 2.40 | Pulmonary toxoplasmosis. ( Campagna, AC, 1997) |
| "Hepatic toxoplasmosis was also present, associated with an elevated serum alkaline phosphatase activity and a minimally elevated lactate dehydrogenase level." | 2.39 | Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. ( Alamy, M; Bonacini, M; Kanel, G, 1996) |
| "Although the incidence of Pneumocystis carinii pneumonia (PCP) among adults infected with human immunodeficiency virus (HIV) has declined, no decline in PCP incidence has been observed among HIV-infected children, and PCP remains the most common serious opportunistic infection among both adults and children in the United States." | 2.39 | Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. ( Feinberg, J; Hughes, WT; Navin, TR; Simonds, RJ, 1995) |
| "Establishing a definitive diagnosis of cerebral toxoplasmosis is difficult in resource limited settings." | 1.42 | Multiple intracerebral lesions in a young male. ( Basavaprabhu, A; Deepak, M; Soundarya, M, 2015) |
| "The current standard treatment for cerebral toxoplasmosis (pyrimethamine/sulfadiazine) often encounters problems of poor tolerability, adverse effects, frequent dropouts and non-availability of pyrimethamine/sulfadiazine in some parts of India." | 1.42 | Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting. ( Goswami, RP; Rahman, M; Ray, Y; Tripathi, SK, 2015) |
| "We describe the course of 36 AIDS patients with cerebral toxoplasmosis and present a review of clinical signs, diagnosis, therapy, and survival times." | 1.31 | [HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients]. ( Evers, S; Fischer, A; Freund, M; Grüneberg, U; Happe, S; Heese, Ch; Husstedt, IW; Kloska, S; Reichelt, D, 2002) |
| "We report one case of successful treatment of cerebral toxoplasmosis in acquired immunodeficiency syndrome (AIDS) with azithromycin combined with pyrimethamine." | 1.30 | [Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient]. ( Dionisio, D; Leoncini, F; Milo, D; Sterrantino, G; Trotta, M, 1997) |
| "Neurotoxoplasmosis was the most frequent presenting symptom of AIDS (53." | 1.30 | [Cerebral toxoplasmosis and AIDS in Martinique]. ( Bourée, P; Dumazedier, D; Magdeleine, C; Sobesky, G, 1997) |
| "Pneumocystis carinii prophylaxis in AIDS patients might be safety withdrawn after effective HAART." | 1.30 | [Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases]. ( de Górgolas Hernández, M; Fernández Guerrero, ML; García Delgado, R; García Vázquez, E, 1999) |
| "Majority of patients with cerebral toxoplasmosis present with focal neurological abnormality in presence of characteristic neuroradiological abnormality and positive antitoxoplasma antibody titer." | 1.30 | Toxoplasmic encephalitis in acquired immunodeficiency syndrome. ( Chaddha, DS; Gupta, RM; Kalra, SP; Sanchetee, PC; Singh, AP, 1999) |
| "Three of 50 (6%) had hemichoreoathetosis." | 1.29 | Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis. ( Andreula, C; Angarano, G; Armenise, S; De Blasi, R; de Mari, M; Maggi, P; Romanelli, C; Zimatore, G, 1996) |
| "Extrapulmonary pneumocystosis is a feature of severe immunosuppression which earlier reports have suggested is limited to patients receiving either no prophylaxis or aerosolised pentamidine." | 1.29 | Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis. ( Carlin, EM; Coker, RJ; Goldin, RD; Harris, JR, 1993) |
| "Pneumocystis carinii pneumonia has been the most common life-threatening opportunistic infection in patients with acquired immunodeficiency syndrome." | 1.29 | Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia. ( Glatt, AE, 1994) |
| "A pregnant woman was diagnosed with central nervous system toxoplasmosis and human immunodeficiency virus infection." | 1.29 | Normal fetal outcome in a pregnancy with central nervous system toxoplasmosis and human immunodeficiency virus infection. A case report. ( Brown, GM; Hedriana, HL; Mitchell, JL; Williams, SB, 1993) |
| "Cerebral toxoplasmosis is the most common opportunistic infection of the central nervous system in AIDS patients." | 1.29 | [Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone]. ( Cardenal, C; Gatell, JM; Guelar, A; Mallolas, J; Miró, JM; Soriano, E; Zamora, L, 1994) |
| "Ten (91%) of these 11 patients with recurrence showed focal persistent enhancement after the initial treatment of toxoplasmosis abscess." | 1.29 | Persistent enhancement after treatment for cerebral toxoplasmosis in patients with AIDS: predictive value for subsequent recurrence. ( Benmelha, Z; Bouvet, E; Casalino, E; Laissy, JP; Lariven, S; Parlier, C; Servois, V; Sibert, A; Soyer, P; Vachon, F, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.88) | 18.7374 |
| 1990's | 80 (70.80) | 18.2507 |
| 2000's | 24 (21.24) | 29.6817 |
| 2010's | 7 (6.19) | 24.3611 |
| 2020's | 1 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Zeng, YM | 1 |
| Lu, YQ | 1 |
| Qin, YY | 1 |
| Chen, YK | 1 |
| Belk, K | 1 |
| Connolly, MP | 2 |
| Schlesinger, L | 1 |
| Ben-Harari, RR | 1 |
| Goswami, RP | 2 |
| Rahman, M | 1 |
| Ray, Y | 1 |
| Tripathi, SK | 1 |
| Deepak, M | 1 |
| Basavaprabhu, A | 1 |
| Soundarya, M | 1 |
| Goodwin, E | 1 |
| Schey, C | 1 |
| Zummo, J | 1 |
| Newman, PM | 1 |
| Wanzira, H | 1 |
| Tumwine, G | 1 |
| Arinaitwe, E | 1 |
| Waldman, S | 1 |
| Achan, J | 1 |
| Havlir, D | 1 |
| Rosenthal, PJ | 1 |
| Dorsey, G | 1 |
| Clark, TD | 1 |
| Cohan, D | 1 |
| Chico, RM | 1 |
| Chandramohan, D | 1 |
| Kiderlen, TR | 1 |
| Liesenfeld, O | 1 |
| Schürmann, D | 4 |
| Schneider, T | 1 |
| Diz, S | 1 |
| Barbolla, I | 1 |
| Egea, M | 1 |
| de Luna, G | 1 |
| Happe, S | 1 |
| Fischer, A | 1 |
| Heese, Ch | 1 |
| Reichelt, D | 1 |
| Grüneberg, U | 1 |
| Freund, M | 1 |
| Kloska, S | 1 |
| Evers, S | 1 |
| Husstedt, IW | 1 |
| Ball, SC | 1 |
| Saito, T | 1 |
| Takeuchi, S | 1 |
| Taguchi, H | 1 |
| Miyoshi, I | 1 |
| van Eijk, AM | 1 |
| Ayisi, JG | 1 |
| ter Kuile, FO | 2 |
| Otieno, JA | 1 |
| Misore, AO | 1 |
| Odondi, JO | 1 |
| Rosen, DH | 1 |
| Kager, PA | 1 |
| Steketee, RW | 2 |
| Nahlen, BL | 1 |
| Filice, G | 1 |
| Carnevale, G | 1 |
| Orsolini, P | 1 |
| Soldini, L | 1 |
| Meroni, V | 1 |
| Comolli, G | 1 |
| Carenzo, L | 1 |
| Lee, MW | 1 |
| Fong, KS | 1 |
| Hsu, LY | 1 |
| Lim, WK | 1 |
| Dedicoat, M | 1 |
| Livesley, N | 1 |
| Ermak, TN | 1 |
| Peregudova, AV | 1 |
| Gruzdev, BM | 1 |
| Amogne, W | 1 |
| Teshager, G | 1 |
| Zenebe, G | 1 |
| Arens, J | 1 |
| Barnes, K | 1 |
| Crowley, N | 1 |
| Maartens, G | 1 |
| Gill, CJ | 2 |
| Macleod, WB | 2 |
| Mwanakasale, V | 2 |
| Chalwe, V | 2 |
| Mwananyanda, L | 2 |
| Champo, D | 2 |
| Mukwamataba, D | 2 |
| Chilengi, R | 2 |
| Thea, DM | 2 |
| Hamer, DH | 2 |
| Mubikayi, L | 1 |
| Mulele, CK | 1 |
| Mulenga, M | 1 |
| Hamel, MJ | 1 |
| Poe, A | 1 |
| Bloland, P | 1 |
| McCollum, A | 1 |
| Zhou, Z | 1 |
| Shi, YP | 1 |
| Ouma, P | 1 |
| Otieno, K | 1 |
| Vulule, J | 1 |
| Escalante, A | 1 |
| Udhayakumar, V | 1 |
| Slutsker, L | 1 |
| Katlama, C | 4 |
| Winstanley, P | 1 |
| Podzamczer, D | 5 |
| Miró, JM | 4 |
| Bolao, F | 2 |
| Gatell, JM | 4 |
| Cosín, J | 2 |
| Sirera, G | 2 |
| Domingo, P | 2 |
| Laguna, F | 1 |
| Santamaría, J | 1 |
| Verdejo, J | 1 |
| Kovacs, JA | 2 |
| Salazar, A | 1 |
| Jiménez, J | 2 |
| Consiglio, E | 1 |
| Santín, M | 3 |
| Casanova, A | 2 |
| Rufí, G | 1 |
| Gudiol, F | 3 |
| Chute, JP | 1 |
| Decker, CF | 1 |
| Cotelingam, J | 1 |
| Opravil, M | 2 |
| Hirschel, B | 1 |
| Lazzarin, A | 1 |
| Heald, A | 1 |
| Pechère, M | 1 |
| Rüttimann, S | 1 |
| Iten, A | 1 |
| von Overbeck, J | 1 |
| Oertle, D | 1 |
| Praz, G | 1 |
| Bessesen, MT | 1 |
| Miller, LA | 1 |
| Cohn, DL | 1 |
| Bartlett, S | 1 |
| Ellison, RT | 1 |
| Bouboulis, DA | 1 |
| Rubinstein, A | 1 |
| Shliozberg, J | 1 |
| Madden, J | 1 |
| Frieri, M | 1 |
| Huber, W | 1 |
| Bautz, W | 1 |
| Classen, M | 1 |
| Schepp, W | 1 |
| Potter, JL | 1 |
| Kofron, WG | 1 |
| Laissy, JP | 1 |
| Soyer, P | 1 |
| Parlier, C | 1 |
| Lariven, S | 1 |
| Benmelha, Z | 1 |
| Servois, V | 1 |
| Casalino, E | 1 |
| Bouvet, E | 2 |
| Sibert, A | 1 |
| Vachon, F | 1 |
| Fernandez, JM | 1 |
| Sadaba, F | 1 |
| Villaverde, FJ | 1 |
| Alvaro, LC | 1 |
| Cortina, C | 1 |
| Marques, LP | 1 |
| Madeira, EP | 1 |
| Santos, OR | 1 |
| Alder, J | 1 |
| Hutch, T | 1 |
| Meulbroek, JA | 1 |
| Clement, JC | 1 |
| Falloon, J | 1 |
| Lavelle, J | 1 |
| Ogata-Arakaki, D | 1 |
| Byrne, A | 1 |
| Graziani, A | 1 |
| Morgan, A | 1 |
| Amantea, MA | 1 |
| Ownby, K | 1 |
| Polis, M | 1 |
| Davey, RT | 1 |
| Rabaud, C | 1 |
| May, T | 1 |
| Amiel, C | 1 |
| Leport, C | 9 |
| Ambroise-Thomas, P | 1 |
| Canton, P | 1 |
| Oksenhendler, E | 1 |
| Charreau, I | 2 |
| Tournerie, C | 1 |
| Azihary, M | 1 |
| Carbon, C | 1 |
| Aboulker, JP | 2 |
| Guelar, A | 1 |
| Mallolas, J | 2 |
| Zamora, L | 2 |
| Cardenal, C | 1 |
| Soriano, E | 2 |
| Bachmeyer, C | 1 |
| Gorin, I | 1 |
| Deleuze, J | 1 |
| Morini, JP | 1 |
| Escande, JP | 1 |
| Brossard, G | 1 |
| Neau, D | 1 |
| Barbeau, P | 1 |
| Pellegrin, JL | 2 |
| Leng, B | 1 |
| Tocchetti, A | 1 |
| Tambini, R | 1 |
| Allegro, A | 1 |
| Longoni, E | 1 |
| Rinaldi, E | 1 |
| Walckenaer, G | 1 |
| Longuet, P | 1 |
| Perronne, C | 1 |
| Lacassin, F | 1 |
| Vildé, JL | 7 |
| Jacobson, MA | 1 |
| Besch, CL | 1 |
| Child, C | 1 |
| Hafner, R | 9 |
| Matts, JP | 1 |
| Muth, K | 1 |
| Wentworth, DN | 1 |
| Neaton, JD | 1 |
| Abrams, D | 1 |
| Rimland, D | 1 |
| Saba, J | 1 |
| Morlat, P | 7 |
| Raffi, F | 1 |
| Hazebroucq, V | 1 |
| Joly, V | 1 |
| Glatt, AE | 1 |
| Kronawitter, U | 1 |
| Jakob, K | 1 |
| Zoller, WG | 1 |
| Rauh, G | 1 |
| Goebel, FD | 1 |
| McCabe, R | 1 |
| Chirurgi, V | 1 |
| Hedriana, HL | 1 |
| Mitchell, JL | 1 |
| Brown, GM | 1 |
| Williams, SB | 1 |
| Murphy, K | 1 |
| Groarke, M | 1 |
| O'Shaughnessy, E | 1 |
| Buckley, A | 1 |
| Mitchell, T | 1 |
| Ruf, B | 3 |
| Bergmann, F | 3 |
| Schüler-Maué, W | 1 |
| Grünewald, T | 4 |
| Gottschalk, HJ | 1 |
| Witt, H | 1 |
| Pohle, HD | 2 |
| Luft, BJ | 7 |
| Korzun, AH | 1 |
| Antoniskis, D | 1 |
| Bosler, EM | 3 |
| Bourland, DD | 1 |
| Uttamchandani, R | 1 |
| Fuhrer, J | 1 |
| Jacobson, J | 1 |
| Ragnaud, JM | 1 |
| Dupon, M | 1 |
| Lacoste, D | 1 |
| Chene, G | 5 |
| Nath, A | 1 |
| Hobson, DE | 1 |
| Russell, A | 1 |
| Vernet, E | 1 |
| Valls, ME | 1 |
| SanMiguel, JG | 1 |
| Martos, A | 1 |
| Ferrer, I | 1 |
| Hagberg, L | 1 |
| Palmertz, B | 1 |
| Lindberg, J | 1 |
| Girard, PM | 1 |
| Landman, R | 1 |
| Gaudebout, C | 2 |
| Olivares, R | 1 |
| Saimot, AG | 1 |
| Jelazko, P | 1 |
| Certain, A | 1 |
| Boué, F | 1 |
| Asensi, V | 1 |
| Cartón, JA | 1 |
| Maradona, JA | 1 |
| de Oña, M | 1 |
| Melón, S | 1 |
| Martínez, A | 1 |
| Asensi, JM | 1 |
| Villar, H | 1 |
| Méndez, FJ | 1 |
| Arribas, JM | 1 |
| Murray-Pulsifer, K | 1 |
| Gudiol, GR | 1 |
| Carlin, EM | 1 |
| Coker, RJ | 1 |
| Goldin, RD | 1 |
| Harris, JR | 1 |
| Hein, R | 1 |
| Brunkhorst, R | 1 |
| Thon, WF | 1 |
| Schedel, I | 1 |
| Schmidt, RE | 1 |
| Caumes, E | 1 |
| Bocquet, H | 1 |
| Guermonprez, G | 1 |
| Rogeaux, O | 1 |
| Bricaire, F | 1 |
| Gentilini, M | 1 |
| Rousseau, F | 2 |
| Pueyo, S | 3 |
| Miro, J | 2 |
| Aubertin, J | 4 |
| Salamon, R | 4 |
| Simonds, RJ | 1 |
| Hughes, WT | 1 |
| Feinberg, J | 1 |
| Navin, TR | 1 |
| Richards, FO | 1 |
| Besnier, JM | 1 |
| Verdier, M | 1 |
| Cotty, F | 1 |
| Fétissof, F | 1 |
| Besancenez, A | 1 |
| Choutet, P | 1 |
| Halme, M | 1 |
| Jokipii, L | 1 |
| Jokipii, AM | 1 |
| Ristola, M | 1 |
| Lähdevirta, J | 1 |
| Antinori, A | 2 |
| Murri, R | 2 |
| Ammassari, A | 1 |
| De Luca, A | 2 |
| Linzalone, A | 1 |
| Cingolani, A | 1 |
| Damiano, F | 1 |
| Maiuro, G | 1 |
| Vecchiet, J | 1 |
| Scoppettuolo, G | 1 |
| Tamburrini, E | 1 |
| Mencarini, P | 1 |
| Visconti, E | 1 |
| Zolfo, M | 1 |
| Siracusano, A | 1 |
| Ortona, E | 1 |
| Jacobson, JM | 2 |
| Davidian, M | 1 |
| Rainey, PM | 1 |
| Raasch, RH | 1 |
| Bonacini, M | 1 |
| Kanel, G | 1 |
| Alamy, M | 1 |
| Carlin, BP | 2 |
| Sargent, DJ | 1 |
| Klinker, H | 1 |
| Langmann, P | 1 |
| Richter, E | 1 |
| Maggi, P | 1 |
| de Mari, M | 1 |
| De Blasi, R | 1 |
| Armenise, S | 1 |
| Romanelli, C | 1 |
| Andreula, C | 1 |
| Zimatore, G | 1 |
| Angarano, G | 2 |
| De Wit, S | 2 |
| O'Doherty, E | 1 |
| Van Glabeke, M | 1 |
| Clumeck, N | 2 |
| Field, AS | 1 |
| Marriott, DJ | 1 |
| Milliken, ST | 1 |
| Brew, BJ | 1 |
| Canning, EU | 1 |
| Kench, JG | 1 |
| Darveniza, P | 1 |
| Harkness, JL | 1 |
| Derouin, F | 1 |
| Letrillart, B | 1 |
| Ecobichon, JL | 1 |
| Luft, B | 2 |
| Trotta, M | 1 |
| Sterrantino, G | 1 |
| Milo, D | 1 |
| Dionisio, D | 1 |
| Leoncini, F | 1 |
| Campagna, AC | 1 |
| Bucher, HC | 1 |
| Griffith, L | 1 |
| Guyatt, GH | 1 |
| de Luis, DA | 1 |
| Fortun, J | 1 |
| Pintado, V | 1 |
| Aller de la Fuente, R | 1 |
| Bourée, P | 1 |
| Dumazedier, D | 1 |
| Magdeleine, C | 1 |
| Sobesky, G | 1 |
| Dequae, L | 1 |
| Torre, D | 1 |
| Casari, S | 1 |
| Speranza, F | 1 |
| Donisi, A | 1 |
| Gregis, G | 1 |
| Poggio, A | 1 |
| Ranieri, S | 1 |
| Orani, A | 1 |
| Chiodo, F | 1 |
| Fiori, G | 1 |
| Carosi, G | 1 |
| Schmidt-Westhausen, A | 1 |
| Reichart, PA | 1 |
| Kadane, JB | 1 |
| Gelfand, AE | 1 |
| Ribera Pascuet, E | 1 |
| López Aldeguer, J | 1 |
| Pérez Elías, MJ | 1 |
| Podzamczer Palter, D | 1 |
| Payen, MC | 1 |
| Sommereijns, B | 1 |
| Montero, A | 1 |
| Cohen, JE | 1 |
| Martínez, DP | 1 |
| Giovannoni, AG | 1 |
| Verhoeff, FH | 1 |
| Brabin, BJ | 1 |
| Hart, CA | 1 |
| Chimsuku, L | 1 |
| Kazembe, P | 1 |
| Broadhead, RL | 1 |
| García Vázquez, E | 1 |
| de Górgolas Hernández, M | 1 |
| García Delgado, R | 1 |
| Fernández Guerrero, ML | 1 |
| Arendt, G | 1 |
| von Giesen, HJ | 1 |
| Hefter, H | 1 |
| Neuen-Jacob, E | 1 |
| Roick, H | 1 |
| Jablonowski, H | 1 |
| Ferrer, E | 1 |
| Ramón, JM | 1 |
| Ribera, E | 1 |
| Cruceta, A | 1 |
| Knobel, H | 1 |
| Polo, R | 1 |
| Leyes, M | 1 |
| Fariñas, MC | 1 |
| Arrizabalaga, J | 2 |
| Martínez-Lacasa, J | 1 |
| Chaddha, DS | 1 |
| Kalra, SP | 1 |
| Singh, AP | 1 |
| Gupta, RM | 1 |
| Sanchetee, PC | 1 |
| Lacascade, C | 1 |
| Conge, AM | 1 |
| Baillat, V | 1 |
| Pages, I | 1 |
| Huguet, MF | 1 |
| Reynes, J | 1 |
| Vendrell, JP | 1 |
| Murakami, T | 1 |
| Nakajima, M | 1 |
| Nakamura, T | 1 |
| Hara, A | 1 |
| Uyama, E | 1 |
| Mita, S | 1 |
| Matsushita, S | 1 |
| Uchino, M | 1 |
| Albrecht, H | 2 |
| Padberg, J | 2 |
| Behnsch, M | 1 |
| Grobusch, M | 2 |
| Vallée, M | 2 |
| Wünsche, T | 2 |
| Suttorp, N | 2 |
| Remington, J | 2 |
| Farthing, C | 1 |
| Holden-Wiltse, J | 1 |
| Harris, C | 1 |
| Jayaweera, DT | 2 |
| Roque, C | 2 |
| Asencio Marchante, R | 1 |
| Lissen Otero, E | 1 |
| Dorrell, L | 1 |
| McCallum, AK | 1 |
| Snow, MH | 1 |
| Ong, EL | 1 |
| Cheng, B | 1 |
| Walker, MJ | 1 |
| Kamya, MR | 1 |
| Kigonya, CN | 1 |
| McFarland, W | 1 |
| Lightman, S | 1 |
| Lynn, WA | 1 |
| Chirgwin, K | 1 |
| Andersen, J | 1 |
| Rajicic, N | 1 |
| McAuliffe, V | 1 |
| Schürmann, M | 1 |
| Iribarren, JA | 1 |
| Garde, C | 1 |
| Rodriguez-Arrondo, F | 1 |
| Blanco, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia[NCT00270530] | Phase 4 | 454 participants | Interventional | 2002-11-30 | Completed | ||
| A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection[NCT00000666] | 600 participants | Interventional | Completed | ||||
| A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS[NCT00000966] | Phase 1 | 45 participants | Interventional | Completed | |||
| A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS[NCT00000674] | 30 participants | Interventional | Completed | ||||
| Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients[NCT00000643] | Phase 2 | 150 participants | Interventional | Completed | |||
| Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii[NCT00000973] | Phase 1 | 26 participants | Interventional | Completed | |||
| Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites[NCT00000826] | Phase 1 | 48 participants | Interventional | Completed | |||
| Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis[NCT00000794] | Phase 2 | 100 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for pyrimethamine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral Therapy | 2017 |
Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy.
Topics: Adult; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antimalar | 2011 |
Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiretroviral Therapy, Highly | 2006 |
[Acute kidney failure caused by sulfadiazine stones. A complication of the therapy of toxoplasmosis in AIDS].
Topics: Acute Kidney Injury; AIDS-Related Opportunistic Infections; Clindamycin; Drug Therapy, Combination; | 1993 |
Issues in toxoplasmosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Clindamycin; Drug Therapy, Combination; Encephalitis | 1993 |
Movement disorders with cerebral toxoplasmosis and AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Basal Ganglia Diseases; Cerebral Cortex; Chorea; Drug | 1993 |
Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; | 1995 |
Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Cats; Dapsone; Drug Therapy, | 1995 |
Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clindamycin; Diarrhea; Duodenal | 1996 |
Pulmonary toxoplasmosis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Biopsy; Humans; Incidence; Lung Diseas | 1997 |
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Administration, Inhalation; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal | 1997 |
[Cerebral toxoplasmosis].
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-HIV Agents; Antiprotozoal Agents; Biopsy; Diagn | 1998 |
[Empirical anti-toxoplasma therapy in cerebral AIDS and Chagas disease. Presentation of 2 cases, review of the literature and proposal of an algorithm].
Topics: Adult; AIDS-Related Opportunistic Infections; Algorithms; Antiprotozoal Agents; Brain Diseases; Chag | 1998 |
Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and Toxoplasma infection.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; | 2000 |
31 trials available for pyrimethamine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-I | 2020 |
Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Antimalarials; CD4 Lymphocy | 2008 |
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Drug Administration Schedule; Drug Therapy, Comb | 1995 |
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Ther | 1995 |
Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Animals; Dapsone; Drug Adm | 1995 |
Administration of pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Administration, Inhalation; Adolescent; Adult; AIDS-Related Opportunistic Infections; Drug Therapy, | 1995 |
Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Biological Availability; Chromatography, High Pressure | 1994 |
Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study.
Topics: AIDS-Related Opportunistic Infections; Animals; Antibodies, Protozoan; Cohort Studies; Drug Toleranc | 1994 |
[Primary prophylaxis against cerebral toxoplasmosis. Efficacy of folinic acid in the prevention of hematologic toxicity of pyrimethamine].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Blood Cell Count; | 1994 |
Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Female; Follow-Up | 1994 |
Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Double-Blind Method; Female; HIV Infections; Humans; M | 1994 |
Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Azithromycin; Drug Administration Sched | 1993 |
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Encephalitis; Female; Huma | 1993 |
Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Dapsone; Drug Therapy, Co | 1993 |
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Topics: Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Dapsone; Drug Combinations; Ence | 1993 |
Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Therapy, C | 1993 |
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Gr
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Antibodies, Protozoan; | 1996 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.
Topics: AIDS-Related Opportunistic Infections; Drug Interactions; Half-Life; HIV Infections; Humans; Male; P | 1996 |
Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Dose-Response Relationship, Drug; Encephalitis; Humans; Pyrim | 1996 |
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clindamycin; Drug Therapy, Comb | 1996 |
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Disease Progression; Double-Blind Metho | 1997 |
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bias; CD4 Lymphocyte Count; Data Inter | 1998 |
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Encephalitis; Female; | 1998 |
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 1997 |
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Therapy, Combination; Encep | 2000 |
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; | 2001 |
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Ani | 2002 |
Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Antiretroviral T | 2002 |
68 other studies available for pyrimethamine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the Vizient Health Systems Data from 2011 to 2017.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antiprotozoal Age | 2018 |
Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clindamycin; Female; Huma | 2015 |
Multiple intracerebral lesions in a young male.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Protozoan; Brain; Drug Combinations; Humans; Immu | 2015 |
Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Cross-Sectional Studies; Drug Combinati | 2009 |
Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretro | 2011 |
[Disseminated cerebral haemorrhages in a patient with HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral | 2011 |
[HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Antiretrovir | 2002 |
A solitary brain lesion in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Therapy, Combination; Femal | 2003 |
Cerebral toxoplasmosis in an AIDS patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Combinations; Humans; Magne | 2003 |
Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Birth Weight; Cohort Studies; Drug Admi | 2004 |
Chemotherapy of toxoplasmic encephalitis in AIDS patients.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Encephalitis; Hum | 1989 |
Optic nerve toxoplasmosis and orbital inflammation as initial presentation of AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Blepharitis; CD4 Lymphocyte Count; Co | 2006 |
[Opportunistic infections in HIV-infected subjects: no wonders].
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Drug Combinations; Early Diagnosis; Fat | 2006 |
Central nervous system toxoplasmosis in adult Ethiopians.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Combinati | 2006 |
Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Drug Ther | 2007 |
Intermittent preventive therapy with sulfadoxine-pyrimethamine during pregnancy: seeking information on optimal dosing frequency.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Disease Susceptibility; Drug Administra | 2007 |
[The impact of the prevention of cerebral toxoplasmosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Brain Abs | 1995 |
Drug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Atovaquone; Clindamycin; Coccidiostats; Humans; Naphthoquinon | 1995 |
Toxoplasmosis in AIDS: keeping the lid on.
Topics: AIDS-Related Opportunistic Infections; Drug Therapy, Combination; Encephalitis; Humans; Pyrimethamin | 1995 |
Severe megaloblastic anemia complicating pyrimethamine therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Megaloblastic; Central Nervous System Diseases | 1995 |
Cerebral toxoplasmosis in childhood and adult HIV infection treated with 1-4 hydroxynaphthoquinone and rapid desensitization with pyrimethamine.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Atovaquone; Child; Desensitizati | 1995 |
[Pyrimethamine-sulfadiazine resistant cerebral toxoplasmosis in AIDS].
Topics: AIDS-Related Opportunistic Infections; Clindamycin; Dexamethasone; Drug Resistance, Microbial; Drug | 1995 |
Sulfadiazine/N4-acetylsulfadiazine crystalluria in a patient with the acquired immune deficiency syndrome (AIDS)
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Hemophilia A; Huma | 1994 |
Persistent enhancement after treatment for cerebral toxoplasmosis in patients with AIDS: predictive value for subsequent recurrence.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Atrophy; Brain; Brain Abscess; Drug Therapy, Com | 1994 |
Cataplexy associated with midbrain lesion.
Topics: Adult; AIDS-Related Opportunistic Infections; Cataplexy; HIV Seropositivity; Humans; Magnetic Resona | 1995 |
Renal alterations induced by sulfadiazine therapy in an AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Drug Therapy, Combination; Female; Humans; Kidney Calc | 1994 |
Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine.
Topics: AIDS-Related Opportunistic Infections; Animals; Clarithromycin; Disease Models, Animal; Dose-Respons | 1994 |
Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Clindamycin; Drug Therapy, Combination; | 1994 |
Toxoplasma gondii infection in advanced HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; Middle Ag | 1994 |
[Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone].
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Atovaquone; Clarithromycin; Clindamycin; Drug | 1994 |
[Recurrence of cerebral toxoplasmosis in 15 AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Brain; Clindamycin; Drug Therapy, Combination; Female; | 1994 |
Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Dapso | 1994 |
Normal fetal outcome in a pregnancy with central nervous system toxoplasmosis and human immunodeficiency virus infection. A case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antibodies, Protozoan; Drug Hypersensitivity; | 1993 |
Pyrimethamine alone as long-term suppressive therapy in cerebral toxoplasmosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Humans; Male; Pyrimethamine; Time Factors; Toxoplasmos | 1994 |
Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Drug Administration Schedule; D | 1993 |
[Cerebral toxoplasmosis in AIDS. 73 cases. Clinical Epidemiology Group on AIDS in Aquitania].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clarithromycin; Cl | 1993 |
Hepatic and pulmonary pneumocystosis during primary prophylaxis for Pneumocystis carinii pneumonia with dapsone/pyrimethamine.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Humans; Liver Dise | 1993 |
Doxycycline and pyrimethamine for toxoplasmic encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Doxycycline; Drug Therapy, Combination; Humans; Male; | 1993 |
[The clinical significance of culturing Toxoplasma gondii on blood and other organic media].
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Blood; Child; Culture Media; Drug Therapy, Co | 1993 |
Two central nervous system infectious diseases in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Hu | 1993 |
Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Com | 1993 |
Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases.
Topics: Acute Kidney Injury; Adult; AIDS-Related Opportunistic Infections; Drug Therapy, Combination; Humans | 1993 |
Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Clindamy | 1995 |
Toxoplasmosis of the bladder in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Antibodies, Protozoan; Biopsy | 1995 |
Toxoplasma pneumonia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Bact | 1995 |
Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Bronchoalveo | 1996 |
Robust Bayesian approaches for clinical trial monitoring.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bayes Theorem; Controlled Clinical Tri | 1996 |
Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis.
Topics: Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Athetosi | 1996 |
Myositis associated with a newly described microsporidian, Trachipleistophora hominis, in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Albendazole; Animals; Anti-Infective Agents; Drug Ther | 1996 |
Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Animals; Antibodies, Protozoan; Antiprotoz | 1996 |
[Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient].
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; D | 1997 |
[HIV infection and Lyell syndrome: a wake-up call concerning anti-inflammatory agents].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Inflammatory | 1997 |
[Cerebral toxoplasmosis and AIDS in Martinique].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Drug Therapy, Combination; Fema | 1997 |
Oral manifestations of toxic epidermal necrolysis (TEN) in patients with AIDS: report of five cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Age | 1998 |
Approaches for optimal sequential decision analysis in clinical trials.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bayes Theorem; Biometry; Clinical Tria | 1998 |
Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Cross-Sectional Studies; Drug Combinati | 1999 |
[Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; A | 1999 |
Long-term course and outcome in AIDS patients with cerebral toxoplasmosis.
Topics: Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antiprot | 1999 |
Toxoplasmic encephalitis in acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Drug Ther | 1999 |
In vitro anti-Toxoplasma gondii antibody production by peripheral blood mononuclear cells in the diagnosis and the monitoring of toxoplasmic encephalitis in AIDS-related brain lesions.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antibodies, Protozoan; Antiprotozoal Agents; Enc | 2000 |
Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Cohort Studies; Drug Comb | 2001 |
[Secondary prevention of opportunistic infections in HIV-infected patients].
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal A | 2001 |
Dapsone/pyrimethamine versus aerosolized pentamidine as prophylaxis against PCP in HIV infection.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents | 1995 |
Preventing opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as To | 1995 |
Opportunistic infections studies update.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Atovaquone; Candidiasi | 1995 |
HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antimalarials; Child; Child, Preschool; Ch | 2001 |
Clinical microbiological case: visual problems in an HIV-positive patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Antiretroviral Therapy, | 2001 |
Empiric treatment of acute Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Encephalitis; Humans; Pyrimethamine; Sulfadiazine; Toxoplasmo | 1992 |